Our science is developing class-leading degrader molecules
Targeted Protein Degradation
Unlike traditional therapies, that transiently inhibit a single function of a protein associated with disease onset or progression, targeted protein degradation (TPD) medicines are designed to use the body’s natural waste disposal system to selectively target and remove pathogenic proteins completely from the body.
Targeted Glues – Next Generation TPD Technology
Based on the ground-breaking science of TPD leader Alessio Ciulli, Amphista is pioneering a next generation TPD technology, which works through a completely novel mechanism and doesn’t rely on cereblon or VHL, which were commonly used in first generation approaches. We have developed a library of unique, patented AMPX warheads which work as Targeted Glues.
Amphista’s Targeted Glues are designed with a chemistry-first approach and offers significant advantages over first generation approaches including class-leading physiochemical properties, which enable broader cell and tissue reach coupled with excellent drug-like and in vivo properties. Oral bioavailability is routinely achieved, and our warheads are inherently brain penetrant, which means we can degrade proteins deep within the CNS in vivo.
Our Eclipsys™ platform
We have brought together an interdisciplinary team of experts, who have built deep scientific know-how and a broad suite of capabilities to guide the discovery and development of our novel protein degraders. We are structurally enabled and use cutting-edge high-content, multiplexed assay technologies to rapidly advance our programs. We leverage advanced data analytics, including AI-ML, and computational modelling to aid our understanding. Our Bioinformatics, Computational Chemists and Cheminformatics teams work closely to unlock unique insights from across internal and external datasets, enabling us to target the right molecules to the right patient populations.
Our projects
We are developing class-leading degrader molecules against some of the most exciting targets, which have clear genetic or clinical relevance in a patient population of high unmet need.
